---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-070582"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2023-12-15T23:59:59+00:00"
generated_at: "2026-06-07T11:57:36.564659+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CHMP positive opinion for CASGEVY conditional EU approval in sickle cell and beta thalassemia

## Summary
- EMA's CHMP adopted positive opinion for conditional approval of CASGEVY (exagamglogene autotemcel) for severe sickle cell disease and transfusion-dependent beta thalassemia.
- CASGEVY is a CRISPR/Cas9 gene-edited therapy jointly developed by CRISPR Therapeutics and Vertex Pharmaceuticals.
- European Commission decision expected in February 2024; conditional marketing authorizations are valid one year, renewable annually.

## SEC filing metadata
- accession: 0000950170-23-070582
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2023-12-15T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017023070582/0000950170-23-070582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017023070582/crsp-20231215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-070582
- JSON: https://secwatch.observer/filing/0000950170-23-070582.json
- Plain text: https://secwatch.observer/filing/0000950170-23-070582.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.